Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ruth Wieland

Internal Medicine Little River, SC Medical Doctor

NPI 1184622607 CMS profile 7904

3361 Highway 9 E, Little River, SC 29566

Open in the dashboard

General payments

$6,815

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruth Wieland of Little River, SC is reported in the CMS Open Payments database as having received $6,815 across 386 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,156 72
2024 General $1,618 67
2023 General $1,289 85
2022 General $1,027 52
2021 General $567 30
2020 General $314 23
2019 General $845 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruth Wieland
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ruth Wieland were reported at $1,156. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ruth Wieland Internal Medicine median Middle half National median
2019 $845 $159 $48–$570 $163
2020 $314 $119 $33–$402 $114
2021 $567 $135 $37–$521 $132
2022 $1,027 $141 $42–$496 $149
2023 $1,289 $149 $45–$519 $160
2024 $1,618 $154 $47–$537 $164
2025 $1,156 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $836 90 payments
  2. Novo Nordisk Inc $810 44 payments
  3. Medtronic, Inc. $556 5 payments
  4. AstraZeneca Pharmaceuticals LP $530 31 payments
  5. Pfizer Inc. $373 24 payments
  6. Amgen Inc. $340 25 payments
  7. Astellas Pharma US Inc $325 20 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $312 19 payments
  9. Janssen Pharmaceuticals, Inc $297 13 payments
  10. Novartis Pharmaceuticals Corporation $236 14 payments
  11. Other $2,200 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,782 384 payments
  2. Education $33 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $461 28 payments
  2. INTERSTIM $376 3 payments
  3. VRAYLAR $356 42 payments
  4. XIFAXAN $312 19 payments
  5. XARELTO $297 13 payments
  6. Wegovy $295 13 payments
  7. FARXIGA $243 17 payments
  8. MYRBETRIQ $238 15 payments
  9. Repatha $238 17 payments
  10. UBRELVY $211 17 payments
  11. Other $5,885 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 170 drugs

Part D claims

11,900

Median for Internal Medicine: 777

Drug cost

$1,756,582

Median for Internal Medicine: $73,373

Branded share of claims

23.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 429 $548,444
Ozempic Semaglutide Brand 268 $404,426
Eliquis Apixaban Brand 97 $121,765
Farxiga Dapagliflozin Propanediol Brand 93 $102,402
Repatha Sureclick Evolocumab Brand 71 $89,858
Xarelto Rivaroxaban Brand 39 $51,586
Jardiance Empagliflozin Brand 42 $39,944
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $33,964
Tresiba Flextouch U-200 Insulin Degludec Brand 21 $30,575
Trulicity Dulaglutide Brand 27 $23,115

The 10 drugs with the highest cost, of 170 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$305,158

Of which drugs: $9,412

Medicare patients

609

Average age 74

Services billed

13,139

402 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 52%
Ischemic heart disease 29%
Diabetes 25%
Chronic kidney disease 24%
Osteoporosis 20%
COPD 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 103 103 $8,427
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 97 $80

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $121
$121 12 —
Ozempic
  • Novo Nordisk Inc $93
$93 268 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $83
$83 12 —
GEMTESA
  • Sumitomo Pharma America, Inc. $76
$76 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record